According to filings with the U.S. Securities and Exchange Commission, Nervonik has raised $52,500,000.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Nervonik
Nervonik is developing next-generation peripheral nerve stimulation technology engineered for dynamic activity. Designed for the rigors of high motion, Nervonik PNS systems set new standards for connectivity, wearability, lead stability, and durability. The PNS systems in use today were never designed for areas of high motion. Nervonik is changing that. Our team developed a novel, patented, trifecta technology that eliminates the technical barriers to biosensing in peripheral nerve stimulation. Nervonik is led by a multidisciplinary team with deep experience across neuromodulation, medical devices, and advanced engineering focused on solving the real-world challenges of peripheral nerve stimulation. Nervonik technology is under development and is not cleared or approved by the U.S. Food and Drug Administration (FDA). Our mission is to develop an advanced, non-drug neuromodulation option intended to address chronic neuropathic pain.

To learn more, visit https://nervonik.com/
LinkedIn: https://www.linkedin.com/company/nervonik-inc/

Contact:
Aydin Babakhani, Chief Executive Officer
https://www.linkedin.com/in/aydinbabakhani/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.